Skip to main content

Table 3 Target coverage comparison

From: Feasibility of constant dose rate VMAT in the treatment of nasopharyngeal cancer patients

  CDR-VMAT VDR-VMAT MCO-VMAT p
PTV-GTV     
Dmean (Gy) 68.41 ± 1.21 68.71 ± 1.28 68.34 ± 0.47 0.42
Dmax (Gy) 71.02 ± 0.93 70.66 ± 1.29 70.44 ± 0.63 0.55
V93 (%) 99.91 ± 0.18 99.93 ± 0.04 99.98 ± 0.02 0.31
V95 (%) 99.72 ± 0.38 99.69 ± 0.13 99.83 ± 0.16 0.38
HI 0.11 ± 0.021 0.12 ± 0.016 0.11 ± 0.026 0.33
CI 0.62 ± 0.64 0.57 ± 0.10 0.65 ± 0.06 0.43
CN 0.62 ± 0.44 0.56 ± 0.11 0.63 ± 0.05 0.26
PTV-CTV     
Dmean (Gy) 56.65 ± 0.47 57.50 ± 1.08 56.15 ± 0.62 1.13
Dmax (Gy) 70.09 ± 0.83 70.76 ± 1.06 70.57 ± 0.43 0.62
V93 (%) 98.74 ± 0.31 99.76 ± 0.16 99.38 ± 0.43 0.01
V95 (%) 98.40 ± 0.48 99.53 ± 0.28 99.07 ± 0.52 0.04
HI 0.28 ± 0.017 0.29 ± 0.012 0.31 ± 0.023 0.01
CI 0.58 ± 0.14 0.57 ± 0.10 0.60 ± 0.06 0.06
CN 0.58 ± 0.04 0.56 ± 0.12 0.57 ± 0.15 0.12